VCP
ONCY

Verus Capital Partners’s Oncolytics Biotech ONCY Stock Holding History

Verus Capital Partners’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-52
Closed – – 1567
2019
Q4 		$0 Buy
+52
New +$59 ﹤0.01% 1545

Other funds holding ONCY

Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBVA
Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Verus Capital Partners's ONCY Position: Q1 2020 in Review

Verus Capital Partners sold out of Oncolytics Biotech (ONCY) in Q1 2020, closing a stake of 52 shares.

Verus Capital Partners first reported a position in ONCY in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 33 funds tracked by Wall St. Rank hold ONCY as of Q1 2020.

  • Verus Capital Partners reported no remaining Oncolytics Biotech position as of Q1 2020 after selling out during the quarter.
  • Verus Capital Partners sold 52 Oncolytics Biotech shares in Q1 2020.
  • Verus Capital Partners first reported a position in Oncolytics Biotech in Q4 2019 and held it in 1 quarter.
  • Verus Capital Partners's Oncolytics Biotech position peaked at $0 in Q4 2019.
  • 33 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.